PDF下载 ( 168 KB)
Effect of Anti-HB transfer factor and Adefovir Combination Therapy on Patients with Chronic-Hepatitis B and Influence on HBV DNA
-
摘要: 目的观察阿德福韦酯联合抗乙型肝炎转移因子对慢性乙型肝炎(CHB)的疗效及对HBV DNA的影响。方法184例CHB患者随机分为治疗组和对照组,治疗组92例为阿德福韦酯和抗乙型肝炎转移因子;对照组92例为单用阿德福韦酯,疗程均为12个月,每三个月分别检测肝功能、乙型肝炎病毒血清学标志物、HBV DNA。其中40例患者(每组20例)进行治疗前、后两次肝穿活检。结果在治疗12个月时,治疗组和对照组的HBV DNA差异有显著性意义(P<0.05),治疗组的HBV DNA表达量明显低于对照组,大部分患者肝组织病理有改善。结论阿德福韦酯联合抗乙型肝炎转移因子能在一定程度上提高治疗CHB的疗效,而其对HBV DNA的影响有待进一步的研究。Abstract: Objective To observe the effect of combined application of anti-HB transfer factor and Adefovir in treating patients with chronic hepatitis B (CHB) and its influence on HBV DNA.Methods 184 patients were enrolled and randomized into two groups: the treated grorp (92 cases) and control group (92cases) .The treated group received anti-HB transfer factor and Adefovir simultaneously for 12 months.The control group received Adefovir alone for 12 months Liver function, virological parameters, serum HBV DNA and HBV DNA were evaluated.Liver biopsy was taken before therapy and after 12 months treament in 40patients.Results After 12months treatment, there was no difference in HBV DNA negative rate between treated group and control groups (P>0.05) .Most of liver histology were improved in 40 patients.Conclusions Combined application of anti-HB transfer factor and 1 Adefovir could enhance the therapeutic effect in treating CHB to certain extent, but effect on HBV DNA should be study further more.
-
Key words:
- Chronic hepatitis B /
- HBV DNA /
- Adefovir /
- anti-HBV transfer factor
-
[1]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324~329. [2]GUO Y, GUO H, ZHANG L, et al.Genomic analysis of anti-hep-atitis B virus (HBV) activity by small instble HBV-producingcells[J].J Virol, 2005, 79 (220∶14392-14403. [3]BENHAMOUY.Treatment algorithm for chronic hepatitis B in HIV-infected patients[J].J Hepatol, 2006, 44 (1 Suppl) ∶S90-S94. [4]Wolters LM, Niesters HG, de Man RA, et al.Nucleoside analoguesfor chronic hepatitis B[J].Eur J Gastroenterol Hepatol, 2001, 13 (12) ∶1499-1506. [5]蒋晔, 徐智儒, 张晓青.抗乙肝新药阿德福韦酯的研究进展[J].中国新药与临床杂志, 2004, 23 (6) ∶373-377. [6]Hadziyannis SJ, Tassopoulos NS, Heathcote EJ, et al.Adefovir dip-ivoxil for the treatment of hepatitis B e antigen-negative chronichepatitis B[J].N Engl J Med, 2003, 348∶800-807. [7]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for hetreatment of hepatitis B e antigen-positive chronic hepatitis B[J].NEngl J Med, 2003, 348∶808-816. [8]Hadziyannis S, Tassopoulos N, Chang TT, et al.three-year studyof adefovir dipivoxil (ADV) demonstrates sustained efficacy in pre-sumed precore mutant chronic hepatitis B patients in a long-termsafety and efficacy study[J].J Hepatol, 2004 (Suppl 1) ∶17 (Ab-stract 46) . [9]Zoulim F.Assessment of treatment efficacy in HBVinfection and dis-ease[J].J Hepatol, 2006, 44 (1 Suppl) ∶S95~99. [10]于建国, 倪介萍, 郭葆玉.慢性乙型肝炎抗病毒药物临床应用现状[J].临床军医杂志, 2002, 30 (6) ∶80~82. -
本文二维码
计量
- 文章访问数: 2268
- HTML全文浏览量: 17
- PDF下载量: 798
- 被引次数: 0
下载:
